Amanda Paschke

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie et al. · New England Journal of Medicine · 2021 · 1.9K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

J. Motsch, Cláudia Murta de Oliveira, V.P. Stus et al. · Clinical Infectious Diseases · 2019 · 404 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Ivan Titov, Richard G. Wunderink, Antoine Roquilly et al. · Clinical Infectious Diseases · 2020 · 225 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Christopher Lucasti, Liviu Vasile, Dorel Săndesc et al. · Antimicrobial Agents and Chemotherapy · 2016 · 181 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

Matthew Sims, Valeri Mariyanovski, Patrick McLeroth et al. · Journal of Antimicrobial Chemotherapy · 2017 · 161 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13